Bentrio®

About Altamira Therapeutics

Altamira Therapeutics operates a dual-track strategy, balancing a commercial-stage consumer health asset with earlier-stage, platform-based therapeutic development. Its core innovation is the xPhore™ platform, a peptide nanoparticle system designed to solve the critical challenge of delivering RNA therapeutics to tissues beyond the liver. The company's mission is to address unmet medical needs in allergy, viral infections, and inner ear disorders, leveraging a partnership-driven out-licensing model for its platform while building a pipeline of proprietary CNS candidates. This structure is intended to mitigate risk and create multiple value inflection points.

Therapeutic Areas